These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21030701)

  • 1. Personalized approaches to clopidogrel therapy: are we there yet?
    Anderson CD; Biffi A; Greenberg SM; Rosand J
    Stroke; 2010 Dec; 41(12):2997-3002. PubMed ID: 21030701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton pump inhibitors and clopidogrel.
    Gaglia MA; Waksman R
    Cardiovasc Ther; 2010 Jun; 28(3):169-76. PubMed ID: 20345494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
    Frelinger AL; Bhatt DL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Lampa M; Brooks JK; Barnard MR; Michelson AD
    J Am Coll Cardiol; 2013 Feb; 61(8):872-9. PubMed ID: 23333143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting.
    Sibbing D; Bernlochner I; Kastrati A; Paré G; Eikelboom JW
    Circ Cardiovasc Interv; 2011 Oct; 4(5):505-13; discussion 513. PubMed ID: 22010189
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacogenetics testing: implications for cardiovascular therapeutics with clopidogrel and warfarin.
    George J; Doney A; Palmer CN; Lang CC
    Cardiovasc Ther; 2010 Jun; 28(3):135-8. PubMed ID: 20557312
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacogenomics of clopidogrel: evidence and perspectives.
    Yin T; Miyata T
    Thromb Res; 2011 Oct; 128(4):307-16. PubMed ID: 21592545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Safety and effectiveness of combining clopidogrel and proton pump inhibitors].
    Calderón Hernanz B; Pinteño Blanco M; Puigventos Latorre F; Martínez-López I
    Farm Hosp; 2009; 33(6):338-9. PubMed ID: 20038395
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinically relevant interaction between clopidogrel and proton pump inhibitors].
    Alban S; Dingermann T; Griese N; Kämmerer W; Schubert-Zsilavecz M; Schulz M; Trenk D; Zagermann-Muncke P
    Pharm Unserer Zeit; 2009; 38(4):370-1. PubMed ID: 19572357
    [No Abstract]   [Full Text] [Related]  

  • 9. Clopidogrel and genetic testing: is it necessary for everyone?
    Goswami S; Cheng-Lai A; Nawarskas J
    Cardiol Rev; 2012; 20(2):96-100. PubMed ID: 22293861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clopidogrel: to test or not to test? That is the question--still.
    Cannon CP
    Clin Chem; 2011 May; 57(5):659-61. PubMed ID: 21402801
    [No Abstract]   [Full Text] [Related]  

  • 11. [A current problem for regulators. Clopidogrel and pharmacokinetics].
    Zündorf I; Dingermann T
    Pharm Unserer Zeit; 2009; 38(4):360-7. PubMed ID: 19572363
    [No Abstract]   [Full Text] [Related]  

  • 12. Current status of clopidogrel pharmacogenomics.
    Giusti B; Gori AM; Marcucci R; Abbate R
    Pharmacogenomics; 2012 Nov; 13(15):1671-4. PubMed ID: 23171330
    [No Abstract]   [Full Text] [Related]  

  • 13. The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.
    Price MJ; Tantry US; Gurbel PA
    Rev Cardiovasc Med; 2011; 12(1):1-12. PubMed ID: 21546883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity.
    Li X; Zhang L; Chen X; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Xu Q; Zhang Y; Li Y; Lu C; Yin T
    Thromb Res; 2013 Oct; 132(4):444-9. PubMed ID: 23993903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?
    Perry CG; Shuldiner AR
    J Hum Genet; 2013 Jun; 58(6):339-45. PubMed ID: 23697979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacogenetics of clopidogrel and its clinical significance].
    Panchenko EP; Komarov AL
    Kardiologiia; 2012; 52(9):44-52. PubMed ID: 23098546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians.
    Tran M; Tafreshi J; Pai RG
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):326-37. PubMed ID: 20938037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics and cardiovascular disease--implications for personalized medicine.
    Johnson JA; Cavallari LH
    Pharmacol Rev; 2013 Jul; 65(3):987-1009. PubMed ID: 23686351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What's new about clopidogrel.
    Cialdella P; Gustapane M; Camaioni C; Biasucci LM
    Minerva Cardioangiol; 2013 Dec; 61(6):683-9. PubMed ID: 24253460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clopidogrel pharmacogenetics: metabolism and drug interactions.
    Close SL
    Drug Metabol Drug Interact; 2011; 26(2):45-51. PubMed ID: 21819266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.